Anastrozole as adjuvant therapy for early-stage breast cancer: Implications of the ATAC trial

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Buzdar, Aman ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant chemotherapy; Aromatase inhibitors; Endocrine therapy; Goserelin; Megestrol acetate; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN;

ADVANCED CANCER; AGE; ARTHRALGIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; HIP FRACTURE; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA AND VOMITING; POSTMENOPAUSE; REVIEW; SPINE FRACTURE; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VEIN THROMBOSIS; WRIST FRACTURE;

EID: 0037768569     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.s.014     Document Type: Review

References (22)

1. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83:1142-1152.
2. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-461.
3. Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) study. J Clin Oncol 2000; 18:3748-3757.
4. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - results of a North American multicenter randomized trial. J Clin Oncol 2000; 18:3758-3767.
5. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 2001; 92:2247-2258.
6. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
7. Buzdar AU, for the ATAC Trialists' Group. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002; 77:295 (Abstract #13).
8. Sainsbury R, for the ATAC Trialists' Group. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2002; 76(suppl 1):S156 (Abstract #633).
9. AstraZeneca Pharmaceuticals LP. 'Arimidex' (anastrozole) tablets: prescribing information [online]. Available at: http://www.fda.gov/cder/approval/index.htm. Accessed November 2002.
10. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467.
12. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320;479-484.
13. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer: Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992; 11:117-120.
14. Ferno M, Stal O, Baldetorp, B, et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 2000; 59:69-76.
15. CRC Trials Unit, Birmingham. Adjuvant Tamoxifen Treatment, Offer More? (aTTom). Protocol. Available at: http://www.cancer.gov/clinicaltrials/view clinicaltrials.aspx?version=1&args=0;ab8574c3-33eb-4b61-995f- 7ad1b77b2bbe. Accessed November 2002.
16. Clinical Trials Service Unit, Radclifffe Infirmary, Oxford. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS). Protocol. April, 1995. ATLAS Office, Oxford, UK: Clinical Trials Service Unit, Radcliffie Infirmary, Oxford OX2 6HE, UK. Available at: http:/www.ctsu.ox.ac.uk/%7Eatlas/index.htm. Accessed November 2002.
17. Braithwaite RS, Law J, Chlebowski RT, et al. A meta-analysis of vascular and neoplastic events associated with tamoxifen [abstract]. Soc Med Decis Making 2000; 22:198.
18. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90:1371-1388.
19. Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95:2006-2016.
20. Buzdar A, Sahmoud T. What next for anastrozole? Ongoing clinical trials. Presented at: VI International Aromatase Conference; October 26-30, 2002; Kyoto, Japan.
21. Robertson JFR. Combined use of goserelin ('Zoladex') and anastrozole ('Arimidex') as second-line therapy in premenopausal women with metastatic breast cancer. Presented at: VI International Aromatase Conference; October 26-30, 2002; Kyoto, Japan.
22. Intergroup (NCIC CTG). MA27. A Randomized Phase III Trial of Exemestane versus anastrozole with or without celecoxib in postmenopausal women with receptor positive primary breast cancer. Available at: http://www.ctg.queensu.ca/public/Clinical_Trials/ph_3_trial_summary.html. Accessed November 2002.